HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease

In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Nugent, Melinda M., Lee, Kyung, He, John Cijiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411988/
https://www.ncbi.nlm.nih.gov/pubmed/25972814
http://dx.doi.org/10.3389/fphys.2015.00132
_version_ 1782368583423098880
author Nugent, Melinda M.
Lee, Kyung
He, John Cijiang
author_facet Nugent, Melinda M.
Lee, Kyung
He, John Cijiang
author_sort Nugent, Melinda M.
collection PubMed
description In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis that acts upstream of major fibrosis signaling pathways. Its key role in renal fibrosis has been validated in vitro and in several murine models of chronic kidney diseases (CKD).
format Online
Article
Text
id pubmed-4411988
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44119882015-05-13 HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease Nugent, Melinda M. Lee, Kyung He, John Cijiang Front Physiol Physiology In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis that acts upstream of major fibrosis signaling pathways. Its key role in renal fibrosis has been validated in vitro and in several murine models of chronic kidney diseases (CKD). Frontiers Media S.A. 2015-04-28 /pmc/articles/PMC4411988/ /pubmed/25972814 http://dx.doi.org/10.3389/fphys.2015.00132 Text en Copyright © 2015 Nugent, Lee and He. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Nugent, Melinda M.
Lee, Kyung
He, John Cijiang
HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
title HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
title_full HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
title_fullStr HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
title_full_unstemmed HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
title_short HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
title_sort hipk2 is a new drug target for anti-fibrosis therapy in kidney disease
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411988/
https://www.ncbi.nlm.nih.gov/pubmed/25972814
http://dx.doi.org/10.3389/fphys.2015.00132
work_keys_str_mv AT nugentmelindam hipk2isanewdrugtargetforantifibrosistherapyinkidneydisease
AT leekyung hipk2isanewdrugtargetforantifibrosistherapyinkidneydisease
AT hejohncijiang hipk2isanewdrugtargetforantifibrosistherapyinkidneydisease

Ejemplares similares